Приказ основних података о документу

dc.creatorBecarević, Mirjana
dc.creatorMirković, Duško
dc.creatorMajkić-Singh, Nada
dc.date.accessioned2019-09-02T11:15:46Z
dc.date.available2019-09-02T11:15:46Z
dc.date.issued2009
dc.identifier.issn1452-8258
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1161
dc.description.abstractThe thrombotic tendency in anti phospholipid syndrome (APS) shares several pathways with atherosclerosis. Atherothrombosis (atherosclerosis superimposed with thromboses) is influenced by nonmodifiable and some modifiable risk factors (smoking, obesity, physical inactivity, alcohol abuse, hyperhomocysteinemia). Therefore, we investigated the association among clinical and serological features of patients with primary APS and potentially modifiable risk factors for the development of atherothrombosis. Also, we compared the analyzed parameters with those in control subjects. Homo cysteine concentrations were detected by HPLC (high performance liquid chromatography), while antiphospholipid antibodies were detected by ELISA. Smokers had elevated levels of homocysteine (chi(2) = 6.22, p lt 0.05). Independently of patients' age, the association between increased levels of homocysteine and history of myocardial infarctions was found (chi(2) = 4.61, p lt 0.05). Hyperhomocysteinemia and smoking are the most important modifiable risk factors for atherothrombosis in primary APS.en
dc.publisherDruštvo medicinskih biohemičara Srbije, Beograd i Versita
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/145010/RS//
dc.rightsopenAccess
dc.sourceJournal of Medical Biochemistry
dc.subjecthyperhomocysteinemiaen
dc.subjectsmokingen
dc.subjectprimary antiphospholipid syndromeen
dc.subjectmyocardial infarctionen
dc.titleHyperhomocysteinemia and smoking in primary antiphospholipid syndromeen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractБецаревић, Мирјана; Мирковић, Душко; Мајкић-Сингх, Нада;
dc.citation.volume28
dc.citation.issue3
dc.citation.spage172
dc.citation.epage175
dc.citation.other28(3): 172-175
dc.citation.rankM52
dc.identifier.wos000270991100005
dc.identifier.doi10.2478/v10011-009-0019-6
dc.identifier.scopus2-s2.0-70350655630
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/129/1159.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу